NASDAQ:SAVA

Cassava Sciences Competitors

$35.64
-0.39 (-1.08 %)
(As of 04/14/2021 03:59 PM ET)
Add
Compare
Today's Range
$35.25
Now: $35.64
$37.51
50-Day Range
$35.96
MA: $48.79
$62.52
52-Week Range
$1.63
Now: $35.64
$117.54
Volume19,821 shs
Average Volume6.62 million shs
Market Capitalization$1.42 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.47

Competitors

Cassava Sciences (NASDAQ:SAVA) Vs. SRPT, ALLK, BPMC, PRGO, SDGR, and GLPG

Should you be buying SAVA stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Cassava Sciences, including Sarepta Therapeutics (SRPT), Allakos (ALLK), Blueprint Medicines (BPMC), Perrigo (PRGO), Schrödinger (SDGR), and Galapagos (GLPG).

Sarepta Therapeutics (NASDAQ:SRPT) and Cassava Sciences (NASDAQ:SAVA) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations and earnings.

Volatility & Risk

Sarepta Therapeutics has a beta of 2.01, indicating that its share price is 101% more volatile than the S&P 500. Comparatively, Cassava Sciences has a beta of 1.47, indicating that its share price is 47% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Sarepta Therapeutics and Cassava Sciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sarepta Therapeutics191202.50
Cassava Sciences00403.00

Sarepta Therapeutics presently has a consensus target price of $150.4762, indicating a potential upside of 104.84%. Cassava Sciences has a consensus target price of $35.3333, indicating a potential downside of 0.86%. Given Sarepta Therapeutics' higher probable upside, research analysts clearly believe Sarepta Therapeutics is more favorable than Cassava Sciences.

Insider & Institutional Ownership

89.7% of Sarepta Therapeutics shares are held by institutional investors. Comparatively, 26.7% of Cassava Sciences shares are held by institutional investors. 5.9% of Sarepta Therapeutics shares are held by insiders. Comparatively, 13.7% of Cassava Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Sarepta Therapeutics and Cassava Sciences' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sarepta Therapeutics$380.83 million15.32$-715,080,000.00($9.71)-7.57
Cassava SciencesN/AN/A$-4,630,000.00($0.27)-132.00

Cassava Sciences has lower revenue, but higher earnings than Sarepta Therapeutics. Cassava Sciences is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Sarepta Therapeutics and Cassava Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sarepta Therapeutics-121.30%-61.62%-23.02%
Cassava SciencesN/A-22.01%-20.85%

Summary

Cassava Sciences beats Sarepta Therapeutics on 7 of the 13 factors compared between the two stocks.

Allakos (NASDAQ:ALLK) and Cassava Sciences (NASDAQ:SAVA) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, valuation and risk.

Insider and Institutional Ownership

65.4% of Allakos shares are held by institutional investors. Comparatively, 26.7% of Cassava Sciences shares are held by institutional investors. 44.8% of Allakos shares are held by company insiders. Comparatively, 13.7% of Cassava Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Allakos and Cassava Sciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Allakos00403.00
Cassava Sciences00403.00

Allakos presently has a consensus target price of $181.50, indicating a potential upside of 68.96%. Cassava Sciences has a consensus target price of $35.3333, indicating a potential downside of 0.86%. Given Allakos' higher probable upside, equities research analysts clearly believe Allakos is more favorable than Cassava Sciences.

Valuation and Earnings

This table compares Allakos and Cassava Sciences' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AllakosN/AN/A$-85,370,000.00($1.89)-56.84
Cassava SciencesN/AN/A$-4,630,000.00($0.27)-132.00

Cassava Sciences is trading at a lower price-to-earnings ratio than Allakos, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Allakos has a beta of 1.02, indicating that its share price is 2% more volatile than the S&P 500. Comparatively, Cassava Sciences has a beta of 1.47, indicating that its share price is 47% more volatile than the S&P 500.

Profitability

This table compares Allakos and Cassava Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AllakosN/A-29.18%-27.70%
Cassava SciencesN/A-22.01%-20.85%

Summary

Cassava Sciences beats Allakos on 5 of the 9 factors compared between the two stocks.

Blueprint Medicines (NASDAQ:BPMC) and Cassava Sciences (NASDAQ:SAVA) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, profitability, analyst recommendations, risk and valuation.

Risk and Volatility

Blueprint Medicines has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500. Comparatively, Cassava Sciences has a beta of 1.47, suggesting that its stock price is 47% more volatile than the S&P 500.

Earnings & Valuation

This table compares Blueprint Medicines and Cassava Sciences' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Blueprint Medicines$66.51 million84.41$-347,690,000.00($7.27)-13.32
Cassava SciencesN/AN/A$-4,630,000.00($0.27)-132.00

Cassava Sciences has lower revenue, but higher earnings than Blueprint Medicines. Cassava Sciences is trading at a lower price-to-earnings ratio than Blueprint Medicines, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Blueprint Medicines and Cassava Sciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Blueprint Medicines06812.67
Cassava Sciences00403.00

Blueprint Medicines presently has a consensus price target of $112.40, indicating a potential upside of 16.03%. Cassava Sciences has a consensus price target of $35.3333, indicating a potential downside of 0.86%. Given Blueprint Medicines' higher possible upside, research analysts plainly believe Blueprint Medicines is more favorable than Cassava Sciences.

Profitability

This table compares Blueprint Medicines and Cassava Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Blueprint Medicines41.08%43.72%33.35%
Cassava SciencesN/A-22.01%-20.85%

Institutional & Insider Ownership

26.7% of Cassava Sciences shares are owned by institutional investors. 3.8% of Blueprint Medicines shares are owned by company insiders. Comparatively, 13.7% of Cassava Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Blueprint Medicines beats Cassava Sciences on 8 of the 14 factors compared between the two stocks.

Perrigo (NYSE:PRGO) and Cassava Sciences (NASDAQ:SAVA) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Analyst Ratings

This is a breakdown of current ratings for Perrigo and Cassava Sciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Perrigo04102.20
Cassava Sciences00403.00

Perrigo presently has a consensus price target of $52.00, suggesting a potential upside of 28.68%. Cassava Sciences has a consensus price target of $35.3333, suggesting a potential downside of 0.86%. Given Perrigo's higher probable upside, equities analysts clearly believe Perrigo is more favorable than Cassava Sciences.

Earnings & Valuation

This table compares Perrigo and Cassava Sciences' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Perrigo$4.84 billion1.11$146.10 million$4.0310.02
Cassava SciencesN/AN/A$-4,630,000.00($0.27)-132.00

Perrigo has higher revenue and earnings than Cassava Sciences. Cassava Sciences is trading at a lower price-to-earnings ratio than Perrigo, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

82.7% of Perrigo shares are held by institutional investors. Comparatively, 26.7% of Cassava Sciences shares are held by institutional investors. 0.3% of Perrigo shares are held by insiders. Comparatively, 13.7% of Cassava Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

Perrigo has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500. Comparatively, Cassava Sciences has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500.

Profitability

This table compares Perrigo and Cassava Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Perrigo-0.13%9.78%4.92%
Cassava SciencesN/A-22.01%-20.85%

Summary

Perrigo beats Cassava Sciences on 7 of the 13 factors compared between the two stocks.

Cassava Sciences (NASDAQ:SAVA) and Schrödinger (NASDAQ:SDGR) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

Insider & Institutional Ownership

26.7% of Cassava Sciences shares are owned by institutional investors. Comparatively, 41.3% of Schrödinger shares are owned by institutional investors. 13.7% of Cassava Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for Cassava Sciences and Schrödinger, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cassava Sciences00403.00
Schrödinger01302.75

Cassava Sciences currently has a consensus price target of $35.3333, suggesting a potential downside of 0.86%. Schrödinger has a consensus price target of $85.50, suggesting a potential upside of 9.69%. Given Schrödinger's higher probable upside, analysts clearly believe Schrödinger is more favorable than Cassava Sciences.

Valuation & Earnings

This table compares Cassava Sciences and Schrödinger's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cassava SciencesN/AN/A$-4,630,000.00($0.27)-132.00
Schrödinger$85.54 million63.80$-24,570,000.00N/AN/A

Cassava Sciences has higher earnings, but lower revenue than Schrödinger.

Profitability

This table compares Cassava Sciences and Schrödinger's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cassava SciencesN/A-22.01%-20.85%
Schrödinger-19.92%-7.25%-5.33%

Galapagos (NASDAQ:GLPG) and Cassava Sciences (NASDAQ:SAVA) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, valuation and profitability.

Risk & Volatility

Galapagos has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500. Comparatively, Cassava Sciences has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500.

Profitability

This table compares Galapagos and Cassava Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Galapagos-70.67%-11.78%-5.58%
Cassava SciencesN/A-22.01%-20.85%

Valuation and Earnings

This table compares Galapagos and Cassava Sciences' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Galapagos$1.00 billion5.26$167.83 million$5.4614.74
Cassava SciencesN/AN/A$-4,630,000.00($0.27)-132.00

Galapagos has higher revenue and earnings than Cassava Sciences. Cassava Sciences is trading at a lower price-to-earnings ratio than Galapagos, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

11.2% of Galapagos shares are owned by institutional investors. Comparatively, 26.7% of Cassava Sciences shares are owned by institutional investors. 2.9% of Galapagos shares are owned by insiders. Comparatively, 13.7% of Cassava Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations for Galapagos and Cassava Sciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Galapagos210502.18
Cassava Sciences00403.00

Galapagos currently has a consensus target price of $143.7273, indicating a potential upside of 78.54%. Cassava Sciences has a consensus target price of $35.3333, indicating a potential downside of 0.86%. Given Galapagos' higher possible upside, equities analysts clearly believe Galapagos is more favorable than Cassava Sciences.

Summary

Galapagos beats Cassava Sciences on 8 of the 13 factors compared between the two stocks.


Cassava Sciences Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$73.46-4.7%$5.56 billion$380.83 million-9.39
Allakos logo
ALLK
Allakos
1.7$107.42-2.8%$5.55 billionN/A-39.20
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$96.87-3.9%$5.39 billion$66.51 million17.87Analyst Report
News Coverage
Perrigo logo
PRGO
Perrigo
2.5$40.38-0.6%$5.36 billion$4.84 billion-672.89
Schrödinger logo
SDGR
Schrödinger
1.3$77.95-3.1%$5.29 billion$85.54 million0.00
Galapagos logo
GLPG
Galapagos
1.3$80.50-2.7%$5.13 billion$1.00 billion-12.20Analyst Report
Gap Down
Atea Pharmaceuticals logo
AVIR
Atea Pharmaceuticals
2.0$54.45-5.1%$4.73 billionN/A0.00Analyst Report
Increase in Short Interest
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$74.80-2.7%$4.52 billionN/A-6.10Analyst Revision
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.19-1.5%$4.31 billion$204.89 million-36.49
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$75.48-4.7%$4.20 billion$6.87 million-7.29Analyst Report
Unusual Options Activity
Analyst Revision
News Coverage
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$67.62-1.8%$4.01 billion$806.43 million-9.58Analyst Report
News Coverage
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$74.47-2.3%$3.88 billion$1.11 billion23.95Analyst Report
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$75.84-1.4%$3.66 billionN/A-21.61Analyst Report
News Coverage
Gap Down
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.3$53.31-2.3%$3.62 billion$117.91 million-10.81Gap Down
I-Mab logo
IMAB
I-Mab
1.2$55.15-10.0%$3.57 billion$4.31 million-1.91Increase in Short Interest
Gap Down
LEGN
Legend Biotech
1.2$26.76-1.1%$3.49 billion$64.39 million0.00Decrease in Short Interest
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$19.13-2.3%$3.41 billion$114.62 million-7.71Analyst Report
News Coverage
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$44.46-5.0%$3.40 billionN/A-5.99News Coverage
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$47.89-1.2%$3.33 billion$306.98 million-6.85
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$21.27-3.1%$3.30 billion$339.08 million-12.37Analyst Report
News Coverage
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$47.35-0.4%$3.29 billion$36.13 million-70.67Unusual Options Activity
Gap Down
Insmed logo
INSM
Insmed
1.2$33.01-4.0%$3.27 billion$136.47 million-12.70
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$89.72-3.6%$3.13 billion$26.52 million-7.90
Alkermes logo
ALKS
Alkermes
1.2$19.21-1.8%$3.00 billion$1.17 billion-41.76
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.6$115.59-3.9%$3.00 billionN/A-57.51Insider Selling
Gap Down
Arvinas logo
ARVN
Arvinas
1.5$62.76-2.3%$3.00 billion$42.98 million-24.52News Coverage
Gap Down
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.0$69.48-1.8%$2.99 billion$421.03 million24.46Analyst Revision
MorphoSys logo
MOR
MorphoSys
0.3$22.68-1.4%$2.94 billion$80.43 million108.01Decrease in Short Interest
Gap Down
Viela Bio logo
VIE
Viela Bio
0.8$53.01-0.0%$2.91 billion$50 million-7.55
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$72.80-0.6%$2.77 billion$644.77 million-10.39
OPKO Health logo
OPK
OPKO Health
1.9$4.20-1.7%$2.77 billion$901.90 million-23.33
Organogenesis logo
ORGO
Organogenesis
1.0$21.90-3.7%$2.70 billion$260.98 million-365.00
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$23.00-3.1%$2.61 billion$306.49 million25.84
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$43.33-2.9%$2.60 billionN/A-23.81
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$32.27-3.8%$2.51 billion$60,000.00-10.02
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$46.03-5.6%$2.50 billion$25 million-9.21Insider Selling
News Coverage
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.4$41.36-2.9%$2.50 billion$2.11 million-8.95Analyst Report
News Coverage
Gap Down
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.98-6.7%$2.46 billion$182.24 million-8.68Analyst Upgrade
Gap Down
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$150.83-2.5%$2.44 billion$120.28 million-152.35Analyst Report
Decrease in Short Interest
News Coverage
Cryoport logo
CYRX
Cryoport
1.9$51.65-1.2%$2.38 billion$33.94 million-89.05
Xencor logo
XNCR
Xencor
1.0$43.17-6.9%$2.33 billion$156.70 million-30.84News Coverage
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$33.21-2.3%$2.30 billion$15 million-17.39Unusual Options Activity
ALX Oncology logo
ALXO
ALX Oncology
1.9$59.45-4.0%$2.29 billionN/A0.00Analyst Report
Insider Selling
Increase in Short Interest
Gap Down
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$43.81-0.5%$2.20 billion$963.01 million13.61News Coverage
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
1.8$27.77-3.4%$2.05 billion$23.90 million-17.25Analyst Report
Analyst Revision
News Coverage
Amarin logo
AMRN
Amarin
1.6$5.10-0.4%$2.00 billion$429.76 million-101.98News Coverage
Gap Down
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.7$28.13-1.2%$1.98 billion$410,000.00-6.12Analyst Report
News Coverage
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.4$53.53-3.4%$1.93 billionN/A-19.90
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$20.64-1.7%$1.92 billion$34.51 million-17.64
IGM Biosciences logo
IGMS
IGM Biosciences
1.7$63.93-2.6%$1.91 billionN/A-27.20Increase in Short Interest
Gap Down
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.